TY - JOUR
T1 - Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset
AU - Chung, Jiil
AU - Negm, Logine
AU - Bianchi, Vanessa
AU - Stengs, Lucie
AU - Das, Anirban
AU - Liu, Zhihui Amy
AU - Sudhaman, Sumedha
AU - Aronson, Melyssa
AU - Brunga, Ledia
AU - Edwards, Melissa
AU - Forster, Victoria
AU - Komosa, Martin
AU - Davidson, Scott
AU - Lees, Jodi
AU - Tomboc, Patrick
AU - Samuel, David
AU - Farah, Roula
AU - Bendel, Anne
AU - Knipstein, Jeffrey
AU - Schneider, Kami Wolfe
AU - Reschke, Agnes
AU - Zelcer, Shayna
AU - Zorzi, Alexandra
AU - McWilliams, Robert
AU - Foulkes, William D.
AU - Bedgood, Raymond
AU - Peterson, Lindsay
AU - Rhode, Sara
AU - Van Damme, An
AU - Scheers, Isabelle
AU - Gardner, Sharon
AU - Robbins, Gabriel
AU - Vanan, Magimairajan Issai
AU - Meyn, M. Stephen
AU - Auer, Rebecca
AU - Leach, Brandie
AU - Burke, Carol
AU - Villani, Anita
AU - Malkin, David
AU - Bouffet, Eric
AU - Huang, Annie
AU - Taylor, Michael D.
AU - Durno, Carol
AU - Shlien, Adam
AU - Hawkins, Cynthia
AU - Getz, Gad
AU - Maruvka, Yosef E.
AU - Tabori, Uri
N1 - Funding Information:
The SickKids Cancer Sequencing (KiCS) program was supported by the Garron Family Cancer Centre with funds from the SickKids Foundation. This research was supported by Meagan's Walk (MW-2014-10), b.r.a.i.n.child Canada, LivWise, SickKids Foundation donors—Harry and Agnieszka Hall, the Zane Cohen Center donors—The Mullin Family and Friends, the Canadian Institutes for Health Research (CIHR) grant (PJT-156006), the CIHR Joint Canada-Israel Health Research Program (MOP—137899), a Stand Up to Cancer (SU2C)—Bristol Myers Squibb Catalyst Research (SU2C-AACR-CT07-17) grant, a Genome Applications Partnership Program (GAPP) grant from Genome Canada, a COG NCORP Research Base Administrative Supplement Request: Landscape of somatic and inherited replication repair deficiency toward a childhood cancer vaccine (3UG1CA189955-08S2), CCS/CIHR/BC Spark Grants: Novel Technology Applications in Cancer Prevention and Early Detection (SPARK-21, 707089—funded by both CCS (Canadian Cancer Society) and BC (Brain Canada)), and St Baldrick's Foundation International Scholar Award (with generous support from the Team Campbell Foundation; Grant No.: 697257, A.D.). Stand Up To Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C.
Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - PURPOSEDiagnosis of Mismatch Repair Deficiency (MMRD) is crucial for tumor management and early detection in patients with the cancer predisposition syndrome constitutional mismatch repair deficiency (CMMRD). Current diagnostic tools are cumbersome and inconsistent both in childhood cancers and in determining germline MMRD.PATIENTS AND METHODSWe developed and analyzed a functional Low-pass Genomic Instability Characterization (LOGIC) assay to detect MMRD. The diagnostic performance of LOGIC was compared with that of current established assays including tumor mutational burden, immunohistochemistry, and the microsatellite instability panel. LOGIC was then applied to various normal tissues of patients with CMMRD with comprehensive clinical data including age of cancer presentation.RESULTSOverall, LOGIC was 100% sensitive and specific in detecting MMRD in childhood cancers (N = 376). It was more sensitive than the microsatellite instability panel (14%, P = 4.3 × 10-12), immunohistochemistry (86%, P = 4.6 × 10-3), or tumor mutational burden (80%, P = 9.1 × 10-4). LOGIC was able to distinguish CMMRD from other cancer predisposition syndromes using blood and saliva DNA (P <.0001, n = 277). In normal cells, MMRDness scores differed between tissues (GI > blood > brain), increased over time in the same individual, and revealed genotype-phenotype associations within the mismatch repair genes. Importantly, increased MMRDness score was associated with younger age of first cancer presentation in individuals with CMMRD (P = 2.2 × 10-5).CONCLUSIONLOGIC was a robust tool for the diagnosis of MMRD in multiple cancer types and in normal tissues. LOGIC may inform therapeutic cancer decisions, provide rapid diagnosis of germline MMRD, and support tailored surveillance for individuals with CMMRD.
AB - PURPOSEDiagnosis of Mismatch Repair Deficiency (MMRD) is crucial for tumor management and early detection in patients with the cancer predisposition syndrome constitutional mismatch repair deficiency (CMMRD). Current diagnostic tools are cumbersome and inconsistent both in childhood cancers and in determining germline MMRD.PATIENTS AND METHODSWe developed and analyzed a functional Low-pass Genomic Instability Characterization (LOGIC) assay to detect MMRD. The diagnostic performance of LOGIC was compared with that of current established assays including tumor mutational burden, immunohistochemistry, and the microsatellite instability panel. LOGIC was then applied to various normal tissues of patients with CMMRD with comprehensive clinical data including age of cancer presentation.RESULTSOverall, LOGIC was 100% sensitive and specific in detecting MMRD in childhood cancers (N = 376). It was more sensitive than the microsatellite instability panel (14%, P = 4.3 × 10-12), immunohistochemistry (86%, P = 4.6 × 10-3), or tumor mutational burden (80%, P = 9.1 × 10-4). LOGIC was able to distinguish CMMRD from other cancer predisposition syndromes using blood and saliva DNA (P <.0001, n = 277). In normal cells, MMRDness scores differed between tissues (GI > blood > brain), increased over time in the same individual, and revealed genotype-phenotype associations within the mismatch repair genes. Importantly, increased MMRDness score was associated with younger age of first cancer presentation in individuals with CMMRD (P = 2.2 × 10-5).CONCLUSIONLOGIC was a robust tool for the diagnosis of MMRD in multiple cancer types and in normal tissues. LOGIC may inform therapeutic cancer decisions, provide rapid diagnosis of germline MMRD, and support tailored surveillance for individuals with CMMRD.
UR - http://www.scopus.com/inward/record.url?scp=85147095194&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147095194&partnerID=8YFLogxK
U2 - 10.1200/JCO.21.02873
DO - 10.1200/JCO.21.02873
M3 - Article
C2 - 36240479
AN - SCOPUS:85147095194
SN - 0732-183X
VL - 41
SP - 766
EP - 777
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 4
ER -